"In Spain, the methadone maintenance programmes provided care for 81,022 patients in 2010, meaning a 4.12% rise compared to the 77,811 in 2009.

"These treatments were carried out in a total of 2,526 methadone-prescribing or methadone-dispensing facilities.

"As far as the location of these facilities is concerned, 50.59% are located in a specific drug dependence treatment centre, 10.62% at prisons, 8.23% at hospitals, 8.09% in mobile units, another 8.09% at mental health centres, 7.65% at health centres, 3.73% in pharmacies and 3% in other facilities.

"Also worthy of special mention is the fact that Buprenorphine+Naloxone (Suboxone®) having recently been included as one of the National Health Service benefits, having made the use thereof affordable in a patient profile stabilised on methadone, at low doses and good progress.

"In Spain, Suboxone® is a medicine subject to special medical prescription (psychotropic) and to restricted medical prescription, classified as a substance of hospital diagnosis.

"According to the data furnished (2011) by the Autonomous Communities and Autonomous Cities, a total of 1,350 individuals have been treated with buprenorphine/naloxone (suboxone). This figure is an initial estimate and will therefore have to be revised and updated."


Government Delegation of National Plan on Drugs (Reitox National Focal Point for Spain), "2012 National Report (2011 Data) to the EMCDDA: Spain: New Development, Trends and in-depth information on selected issues" (Madrid, Spain: DGPNSD, Dec. 2012), p. 191.